A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Relapsed Small Cell Lung Cancer After Two or More Prior Lines of Treatment

The main aim of this study is to:

* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only
* evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2
* evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3